Literature DB >> 18806838

Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma.

V Bachanova1, C G Brunstein, L J Burns, J S Miller, X Luo, T Defor, J-A H Young, D J Weisdorf, M Tomblyn.   

Abstract

Non-myeloablative (NMA) allogeneic donor SCT for patients with relapsed lymphoma is associated with lower treatment-related mortality (TRM). However, the impact of conditioning intensity on post transplant infections remains unclear. We evaluated infections in 141 consecutive patients with lymphoma who were allografted using NMA (n=76) or myeloablative (MA; n=65) conditioning regimens. Using infection incidence density per 1000 patient days, we accounted for all infectious episodes during the first post transplant year. Before neutrophil engraftment, the NMA cohort had a 53% lower rate of bacterial infection (relative risk=0.47; P=0.06), whereas after engraftment the density of bacterial infections was similar in the two groups. In the first month, both invasive fungal infections and viral infections were twofold less frequent (P=0.22; P=0.06) in NMA patients. Late viral and fungal infections as well as CMV reactivation were infrequent after either conditioning intensity. The 1-year infection-related mortality was significantly lower after NMA conditioning (NMA 9% (3-16%) vs MA 22% (11-40%); P=0.03). NMA allogeneic transplantation for lymphoma patients results in substantially fewer early infections and lower infection-related deaths, although the similar frequency of later infections suggests that immune reconstitution is delayed with either conditioning intensity.

Entities:  

Mesh:

Year:  2008        PMID: 18806838     DOI: 10.1038/bmt.2008.313

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Shih Hann Su; Valérie Martel-Laferrière; Annie-Claude Labbé; David R Snydman; David Kent; Michel Laverdière; Claire Béliveau; Tanya Logvinenko; Sandra Cohen; Silvy Lachance; Thomas Kiss; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

2.  Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.

Authors:  Jo-Anne H Young; Brent R Logan; Juan Wu; John R Wingard; Daniel J Weisdorf; Cathryn Mudrick; Kristin Knust; Mary M Horowitz; Dennis L Confer; Erik R Dubberke; Steven A Pergam; Francisco M Marty; Lynne M Strasfeld; Janice Wes M Brown; Amelia A Langston; Mindy G Schuster; Daniel R Kaul; Stanley I Martin; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-25       Impact factor: 5.742

3.  Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time.

Authors:  Celalettin Ustun; Jiří Slabý; Ryan M Shanley; Jan Vydra; Angela R Smith; John E Wagner; Daniel J Weisdorf; Jo-Anne H Young
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-21       Impact factor: 5.742

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 5.  Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.

Authors:  Minoo Battiwalla; André Tichelli; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-03       Impact factor: 5.742

6.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 8.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

Review 9.  Cytomegalovirus pneumonia in hematopoietic stem cell recipients.

Authors:  Giovanna Travi; Steven A Pergam
Journal:  J Intensive Care Med       Date:  2013-02-06       Impact factor: 3.510

10.  Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant.

Authors:  Celalettin Ustun; Veronika Bachanova; Ryan Shanley; Margaret L MacMillan; Navneet S Majhail; Mukta Arora; Claudio Brunstein; John E Wagner; Daniel J Weisdorf
Journal:  Leuk Lymphoma       Date:  2013-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.